June 18, 2026
Generic drugs, premium drama
Hospitals and universities repurposing drugs at 90% lower cost
Cheap old drugs, huge hopes — but commenters say the rulebook is the real villain
TLDR: Hospitals and universities are testing new uses for cheap existing drugs at a tiny fraction of the usual cost, raising hopes for more affordable treatments. Commenters love the idea but are split between optimism and frustration, warning that legal red tape and limits of old drugs could stop patients from benefiting.
A quietly radical idea just crashed into the chat: hospitals and universities are finding new uses for old drugs and doing the testing for up to 90% less money than big pharmaceutical companies. That means a cheap generic pill once made for one illness could end up helping with something completely different — like blindness, Covid, or preventing breast cancer — without the usual blockbuster price tag. On paper, it sounds like a feel-good miracle. In the comments? Instant reality check.
The biggest mood swing came from people asking: great, but how do patients actually hear about these studies, and can doctors even officially use the results? One commenter cut straight to the bureaucratic heartbreak, warning that even if a study shows a generic drug works for a new illness, there may be no clean legal path to make that use officially approved unless the manufacturer plays along. Translation: the science might be exciting, but the paperwork is giving villain energy.
Then the thread got personal. One supporter of Cures Within Reach brought up Huntington’s disease in their family, arguing this kind of research matters most when there’s zero profit motive for industry. But not everyone was ready to celebrate. Another commenter basically slammed the brakes, saying repurposing is helpful, sure, but it won’t magically cure everything, especially brutal conditions like long Covid and chronic fatigue syndrome. So the community verdict? Hopeful, emotional, and very, very suspicious of the system getting in its own way.
Key Points
- •Research led by King’s College London describes a parallel drug innovation system in hospitals and universities focused on repurposing existing drugs.
- •The study says hospitals and universities conduct substantial numbers of late-stage clinical trials at funded costs below 10% of pharmaceutical companies’ reported costs.
- •The article identifies expertise, risk and capital as key barriers in drug development, and says these barriers are lower when repurposing generic drugs.
- •Examples cited include repurposing a cancer drug for a leading cause of blindness, switching a breast-cancer treatment to prevention, and using an old anti-inflammatory drug for Covid.
- •The article says pharmaceutical companies typically lose interest in repurposing after drugs become generic, while governments are beginning programmes to formally recognise academic and hospital-led repurposing research.